AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE
The purpose of this study is to evaluate the efficacy and safety of rimegepant when administered during the peri-menstrual period (PMP) for intermittent prevention of migraine in women who experience menstrual migraine attacks.
Inclusion Criteria:
Exclusion Criteria:
ClinicalTrials.gov_Inquiries@pfizer.com1-800-718-1021
Evansville, Indiana 47714, United States
Philadelphia, Pennsylvania 19107, United States
McLean, Virginia 22101, United States
CABA, Buenos Aires 1428, Argentina
Buenos Aires, Buenos Aires F.D. C1012AAR, Argentina
Cordoba Capital, Córdoba Province 5004, Argentina
Chongqing, Chongqing Municipality 400016, China
Nanjing, Jiangsu 210011, China
Qingdao, 266042, China
Mumbai, Maharashtra 400008, India
Nashik, Maharashtra 422005, India
Lucknow, Uttar Pradesh 226014, India
Avezzano, L'aquila 67051, Italy
Kyoto-shi Shimogyo-ku, Kyoto 600-8811, Japan
Shibuya-ku, Tokyo 151-0051, Japan
Guadalajara, Jalisco 44130, Mexico
Lublin, Lublin Voivodeship 20-582, Poland
Gangseo-gu, Seoul-teukbyeolsi [seoul] 07804, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 01830, South Korea
Seoul, Seoul-teukbyeolsi [seoul] 03722, South Korea